Biogen Inc. stock holds near top of 52-week range after EMPAVELI data update

Published on 09/21/2026 at 15:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Biogen Inc. stock closed at USD 215.50 on Nasdaq on September 18, 2026, near the upper end of its 52-week range. New EMPAVELI Phase 3 data in adolescents published on September 17, 2026 adds a fresh clinical catalyst for the biotech group.

Fotorealistisches Biotech-Labor in Cambridge MA mit Forscherin am Mikroskop und Blick auf den Charles River — Biogen Inc. Neurowissenschaftslabor in Cambridge MA zeigt Forscherin bei Gehirngewebeanalyse unter Mikroskop ISIN US09062X1037, Illustration mit AI erstellt.

Biogen Inc. stock (ISIN US09062X1037) closed at USD 215.50 on Nasdaq on September 18, 2026, leaving the shares close to the upper end of their 52-week range between USD 135.39 and USD 225.80 and corresponding to a market capitalization of around USD 31.84 billion as of that date per exchange data cited in an overview by MarketBeat.

EMPAVELI study data provides fresh clinical catalyst

As MarketBeat reports, the most recent FDA-related event for Biogen occurred on September 17, 2026, when the company announced publication of results from a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating EMPAVELI (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology, highlighting reduced proteinuria in adolescents with kidney disease.

According to the same EMPAVELI update summarized by MarketBeat on September 21, 2026, the event was categorized as a results publication rather than a new approval, but it strengthens the evidence base for EMPAVELI in a younger patient population and adds to Biogen's nephrology-focused portfolio.

Earnings growth expectations and recent quarterly figures

Beyond the new clinical data, Biogen's latest reported quarterly figures provide investors with a reference point for the group’s financial trajectory in 2026. According to an earnings and valuation overview from MarketBeat, Biogen last reported earnings on July 29, 2026 for its most recent quarter, posting earnings per share of USD 3.60, which exceeded analysts’ consensus estimate of USD 2.94 by USD 0.66 and thus represented a positive surprise of about 22.4 percent in EPS terms.

As the same July 29, 2026 earnings summary from MarketBeat notes, Biogen’s revenue in that quarter increased by 3.4 percent year on year, underlining that the company is still achieving modest top-line growth while delivering a stronger improvement at the earnings level.

Looking ahead, earnings growth is expected to continue. The same analyst overview from MarketBeat indicates that Biogen’s earnings per share are projected to grow from USD 12.41 to USD 16.11 in the coming year, implying expected EPS growth of 29.81 percent based on current consensus estimates for fiscal year 2026 relative to 2025.

Valuation metrics and year-to-date performance

Alongside the fundamental trajectory, valuation metrics and price performance frame Biogen stock’s appeal in the biotech space. According to the same stock overview on MarketBeat, Biogen’s price-to-earnings ratio currently stands at 38.14, which is described as less expensive than the broad market’s average P/E of about 44.66, suggesting that despite its premium biotech profile the stock is not trading at the very top of the market’s valuation range.

The same performance data set from MarketBeat shows that Biogen’s share price was USD 175.99 at the start of 2026 and has since risen to USD 215.50, an increase of 22.5 percent year to date, meaning that the stock has clearly outperformed many defensive sectors in 2026 while remaining within its 52-week band.

Nasdaq trading data and upcoming earnings date

For investors watching the tape, Biogen’s recent Nasdaq trading data provide additional context. The FDA events overview on MarketBeat lists a closing price of USD 215.50 for Biogen shares on Nasdaq on September 18, 2026 at 4:00 p.m. Eastern Time, with extended-hours trading later that day at USD 217.00, up USD 1.50 or 0.70 percent as of 7:58 p.m. Eastern.

Additionally, the calendar section of the Biogen stock page on MarketBeat shows July 29, 2026 as the last earnings date and lists October 28, 2026 as the estimated next earnings release, giving investors a preliminary timeline for when the company may next update the market on its financial results.

Biogen stock price and range positioning

Biogen Inc. stock most recently finished regular trading on Nasdaq at USD 215.50 on September 18, 2026, down 1.62 percent compared with the prior close but still near the upper end of its 52-week range between USD 135.39 and USD 225.80, with the session implying a market capitalization of approximately USD 31.84 billion and trading volume of about 2,630,000 shares based on data cited by MarketBeat.